Generic Name and Formulations:
Lincomycin 300mg/mL; soln for IV, IM, subconjunctival inj after dilution; contains benzyl alcohol 9.45mg.
Indications for LINCOCIN:
Serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Reserved for penicillin-allergic patients or for whom penicillin is inappropriate.
IV doses: infuse over at least 60mins. Serious infections: 600mg IM every 24hrs or 600mg–1g IV every 8–12hrs. More severe infections: 600mg IM every 12hrs (or more often), or doses up to max 8g/day IV have been used for life-threatening infections. Subconjunctival inj: 75mg subconjunctivally will result in ocular fluid levels of antibiotic with MICs sufficient for most susceptible pathogens. Severe renal impairment: give 25–30% of recommended dose.
<1month: not established. ≥1month: Serious infections: 10mg/kg IM every 24hrs. More severe infections: 10mg/kg IM every 12hrs or more often. Depending on severity of infection, may also give 10–20mg/kg/day IV in divided doses.
Risk of severe colitis (may be fatal); consider C. difficile-associated diarrhea (CDAD) in all patients presenting with diarrhea after use; discontinue if CDAD suspected/confirmed or if significant diarrhea occurs. Not for treating minor bacterial or viral infections, or meningitis. History of GI disease (esp. colitis). History of asthma or significant allergies. Severe renal impairment. Hepatic dysfunction. Monitor liver, kidney, and blood counts with prolonged and high-dose therapy. Premature infants (Gasping Syndrome from benzyl alcohol). Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant erythromycin: not recommended. May potentiate neuromuscular blocking agents.
Nausea, vomiting, diarrhea, colitis, hematologic effects (eg, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura), hypersensitivity reactions (discontinue if occurs), rash, urticaria, vaginitis, jaundice, abnormal LFTs, azotemia, oliguria, proteinuria, cardiopulmonary arrest and hypotension with rapid IV administration, superinfection, CDAD.
Vials (2mL, 10mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia